Akrevia Therapeutics is a biopharmaceutical company focused on developing highly-potent, targeted immuno-oncology therapeutics. The company’s proprietary Aklusion™ platform technology allows biologics to be specifically activated in the tumor microenvironment, and with precisely tailored properties, expanding the universe of natural immune-activating proteins that can be safely delivered. Akrevia is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for patients living with cancer. To learn more, please visit www.akrevia.com. The company is financed by blue chip investors F-Prime Capital Partners and Atlas Venture. Akrevia has licensed key technology from Thomas Jefferson University and City of Hope. The company is located in Cambridge, Massachusetts.
View Top Employees from Akrevia Therapeutics, Inc.Website | http://www.akrevia.com |
Revenue | $7 million |
Funding | $30 million |
Employees | 109 (109 on RocketReach) |
Founded | 2015 |
Address | 610 Main St, Cambridge, Massachusetts 02139, US |
Phone | (212) 899-9730 |
Technologies |
JavaScript,
HTML,
Font Awesome
+22 more
(view full list)
|
Industry | Biotechnology, Business Services General, Pharmaceuticals, Business Services, Immunotherapeutics, Executive Office |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541714 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies |
Looking for a particular Akrevia Therapeutics, Inc. employee's phone or email?
The Akrevia Therapeutics, Inc. annual revenue was $7 million in 2023.
Rene Russo is the President and Chief Executive Officer of Akrevia Therapeutics, Inc..
109 people are employed at Akrevia Therapeutics, Inc..
Akrevia Therapeutics, Inc. is based in Cambridge, Massachusetts.
The NAICS codes for Akrevia Therapeutics, Inc. are [541714, 5417, 54171, 54, 541].
The SIC codes for Akrevia Therapeutics, Inc. are [873, 87].